Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapyMarjan Mojtabavi Naeini, Nicola Waddell, Conrad Leonard et al.|Nature Communications|2023Cited by 31
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutationSubotheni Thavaneswaran, David M. Thomas, Frank Lin et al.|npj Precision Oncology|2024Cited by 6
623P Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12F.P. Lin, David M. Thomas, A. Mersiades et al.|Annals of Oncology|2024Cited by 1
Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind studyMeera Agar, Eng‐Siew Koh, Anna K. Nowak et al.|BMJ Supportive & Palliative Care|2023Cited by 0
280. MULTI-OMIC FEATURES OF OESOPHAGEAL ADENOCARCINOMA PATIENTS PRE-TREATED WITH PREOPERATIVE NEOADJUVANT THERAPYMarjan Mojtabavi Naeini, Nicola Waddell, Felicity Newell et al.|Diseases of the Esophagus|2022Cited by 0